Grand Pharmaceutical's CBT-001 meets primary endpoint in Phase III pterygium trial

• Grand Pharmaceutical reported on November 5, 2026, that CBT-001 met the primary endpoints in an international Phase III pterygium trial.
• Both doses improved eye redness and reduced lesion length compared with vehicle treatment; additional analyses are ongoing.
• Superficial punctate keratitis was the most common adverse event at the lower dose; most cases resolved with artificial tears.
• Developer Cloudbreak Pharma plans to discuss the findings and potential clinical and regulatory next steps with the FDA.
• The group holds exclusive manufacturing and commercialization rights in mainland China, Hong Kong, Macao and Taiwan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261105-12400965), on November 05, 2026, and is solely responsible for the information contained therein.